anti her2 erbb2 rabbit polyclonal primary antibody (Cell Signaling Technology Inc)

Cell Signaling Technology Inc is a verified supplier

Cell Signaling Technology Inc manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Cell Signaling Technology Inc anti her2 erbb2 rabbit polyclonal primary antibody

<t>HER2</t> expression and cell cycle distribution in JIMT‐1 and N87 cells. a) HER2 expression in JIMT‐1 and N87 cells stained via ICC (red, Alexa 594‐stained HER2; blue, Hoechst‐stained nuclei, scale bar, 10 µm). Cell cycle distribution in b) JIMT‐1 and c) N87 cells treated with T‐DM1, LCB‐ADC1, or LCB‐ADC2 at 0.25 µg mL −1 for 72 h. Cells stained with propidium iodide (PI) were analyzed by flow cytometry.

Anti Her2 Erbb2 Rabbit Polyclonal Primary Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti her2 erbb2 rabbit polyclonal primary antibody/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
Price from $9.99 to $1999.99

anti her2 erbb2 rabbit polyclonal primary antibody - by Bioz Stars, 2023-06

96/100 stars

Images

1) Product Images from "An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers"

Article Title: An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

Journal: Advanced Science

doi: 10.1002/advs.202102414

HER2 expression and cell cycle distribution in JIMT‐1 and N87 cells. a) HER2 expression in JIMT‐1 and N87 cells stained via ICC (red, Alexa 594‐stained HER2; blue, Hoechst‐stained nuclei, scale bar, 10 µm). Cell cycle distribution in b) JIMT‐1 and c) N87 cells treated with T‐DM1, LCB‐ADC1, or LCB‐ADC2 at 0.25 µg mL −1 for 72 h. Cells stained with propidium iodide (PI) were analyzed by flow cytometry.

Figure Legend Snippet: HER2 expression and cell cycle distribution in JIMT‐1 and N87 cells. a) HER2 expression in JIMT‐1 and N87 cells stained via ICC (red, Alexa 594‐stained HER2; blue, Hoechst‐stained nuclei, scale bar, 10 µm). Cell cycle distribution in b) JIMT‐1 and c) N87 cells treated with T‐DM1, LCB‐ADC1, or LCB‐ADC2 at 0.25 µg mL −1 for 72 h. Cells stained with propidium iodide (PI) were analyzed by flow cytometry.

Techniques Used: Expressing, Staining, Flow Cytometry

Therapeutic efficacy of LCB‐ADCs in HER2‐positive CDX models and microtubule interruption and mitotic arrest in CDX tumor tissue. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in JIMT‐1 cells. Drugs were i.v. injected at 2 mg kg −1 once (↑), n = 5. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC1 or 2). b) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in N87 cells. Drugs were i.v. injected at 2 mg kg −1 once (↑), n = 5. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC 2). HER2 expression in tumor tissue was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c) In vivo microtubule interruption and mitotic arrest by LCB‐ADC1. Mice bearing N87 tumors were i.v. administered with T‐DM1, LCB‐ADC1 at 5 mg kg −1 once. After 10 d, the tumors were isolated, fixed, and stained with anti‐ α ‐tubulin (upper, blue, Hoechst‐stained nuclei; red, Alexa 594‐stained α ‐tubulin, scale bar; 10 µm) or antiphosphohistone H3 (PHH3) (lower, blue, hematoxylin‐stained nuclei; brown, 3,3′‐diaminobenzidine (DAB)‐stained PHH3, scale bar, 100 µm). d) Effect of LCB‐ADC1 in N87 cells. Drugs were i.v. injected at 0.2, 1 or 5 mg kg −1 , once a week for 4 weeks (↑), n = 8. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC1).

Figure Legend Snippet: Therapeutic efficacy of LCB‐ADCs in HER2‐positive CDX models and microtubule interruption and mitotic arrest in CDX tumor tissue. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in JIMT‐1 cells. Drugs were i.v. injected at 2 mg kg −1 once (↑), n = 5. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC1 or 2). b) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in N87 cells. Drugs were i.v. injected at 2 mg kg −1 once (↑), n = 5. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC 2). HER2 expression in tumor tissue was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c) In vivo microtubule interruption and mitotic arrest by LCB‐ADC1. Mice bearing N87 tumors were i.v. administered with T‐DM1, LCB‐ADC1 at 5 mg kg −1 once. After 10 d, the tumors were isolated, fixed, and stained with anti‐ α ‐tubulin (upper, blue, Hoechst‐stained nuclei; red, Alexa 594‐stained α ‐tubulin, scale bar; 10 µm) or antiphosphohistone H3 (PHH3) (lower, blue, hematoxylin‐stained nuclei; brown, 3,3′‐diaminobenzidine (DAB)‐stained PHH3, scale bar, 100 µm). d) Effect of LCB‐ADC1 in N87 cells. Drugs were i.v. injected at 0.2, 1 or 5 mg kg −1 , once a week for 4 weeks (↑), n = 8. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC1).

Techniques Used: Injection, Standard Deviation, Expressing, Staining, In Vivo, Isolation

Therapeutic efficacy of LCB‐ADCs in HER2‐positive GC PDX models. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in an HER2 +++ GC PDX model. The drugs were i.v. injected at 5 mg kg −1 once (↑), n = 5. b) Effect of LCB‐ADC1, LCB‐ADC3, T‐DM1 in an HER2 ++ GC PDX model. Drugs were i.v. injected at 5 mg kg −1 twice (↑), n = 5. Data values are a mean ± standard deviation. ** p < 0.01 (T‐DM1 vs LCB‐ADC3, single or repeated treatment). HER2 expression in tumor tissues was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c,d) Mice bearing HER2 ++ GC patient‐derived tumors were i.v. administered with LCB‐ADC1, LCB‐ADC3, or T‐DM1 at 5 mg kg −1 , every other week for 4 weeks, n = 5. At the end of the experiment, c) tumors were isolated, photographed (scale bar, 1 cm) and d) weighed. Data values are mean ± standard deviation. * p < 0.05 (T‐DM1 vs LCB‐ADC1), ** p < 0.01 (T‐DM1 vs LCB‐ADC3).

Figure Legend Snippet: Therapeutic efficacy of LCB‐ADCs in HER2‐positive GC PDX models. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in an HER2 +++ GC PDX model. The drugs were i.v. injected at 5 mg kg −1 once (↑), n = 5. b) Effect of LCB‐ADC1, LCB‐ADC3, T‐DM1 in an HER2 ++ GC PDX model. Drugs were i.v. injected at 5 mg kg −1 twice (↑), n = 5. Data values are a mean ± standard deviation. ** p < 0.01 (T‐DM1 vs LCB‐ADC3, single or repeated treatment). HER2 expression in tumor tissues was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c,d) Mice bearing HER2 ++ GC patient‐derived tumors were i.v. administered with LCB‐ADC1, LCB‐ADC3, or T‐DM1 at 5 mg kg −1 , every other week for 4 weeks, n = 5. At the end of the experiment, c) tumors were isolated, photographed (scale bar, 1 cm) and d) weighed. Data values are mean ± standard deviation. * p < 0.05 (T‐DM1 vs LCB‐ADC1), ** p < 0.01 (T‐DM1 vs LCB‐ADC3).

Techniques Used: Injection, Standard Deviation, Expressing, Staining, Derivative Assay, Isolation

In vivo efficacy of LCB‐ADC3 at a low dose in an HER2 ++ GC PDX model. a) Tumor growth delay curves and b) survival rate when the tumor volume reached 1500 mm 3 . Mice bearing patient‐derived tumors were i.v. administered LCB‐ADC3 (0.5 or 1 mg kg −1 ) or T‐DM1 (4 mg kg −1 ), weekly for 4 weeks (↑), n = 5. Data values are the mean ± standard deviation. ** p < 0.01 (T‐DM1 vs LCB‐ADC3, 0.05 mg kg −1 ), *** p < 0.001 (T‐DM1 vs LCB‐ADC3, 1 mg kg −1 ).

Figure Legend Snippet: In vivo efficacy of LCB‐ADC3 at a low dose in an HER2 ++ GC PDX model. a) Tumor growth delay curves and b) survival rate when the tumor volume reached 1500 mm 3 . Mice bearing patient‐derived tumors were i.v. administered LCB‐ADC3 (0.5 or 1 mg kg −1 ) or T‐DM1 (4 mg kg −1 ), weekly for 4 weeks (↑), n = 5. Data values are the mean ± standard deviation. ** p < 0.01 (T‐DM1 vs LCB‐ADC3, 0.05 mg kg −1 ), *** p < 0.001 (T‐DM1 vs LCB‐ADC3, 1 mg kg −1 ).

Techniques Used: In Vivo, Derivative Assay, Standard Deviation

Mitotic arrest of HER2‐positive GC PDX tumor tissue. a,b) Mice bearing HER2‐positive PDX tumors were i.v. administered with a) LCB‐ADC2, b) LCB‐ADC3 or T‐DM1 at 5 mg kg −1 once, n = 5. After 1, 4, and 7 d, the tumors were isolated, fixed, and stained with antiphosphohistone H3 (PHH3) (blue, hematoxylin‐stained nuclei; brown, DAB‐stained PHH3, scale bar, 100 µm). Data values are a mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC2 or 3).

Figure Legend Snippet: Mitotic arrest of HER2‐positive GC PDX tumor tissue. a,b) Mice bearing HER2‐positive PDX tumors were i.v. administered with a) LCB‐ADC2, b) LCB‐ADC3 or T‐DM1 at 5 mg kg −1 once, n = 5. After 1, 4, and 7 d, the tumors were isolated, fixed, and stained with antiphosphohistone H3 (PHH3) (blue, hematoxylin‐stained nuclei; brown, DAB‐stained PHH3, scale bar, 100 µm). Data values are a mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC2 or 3).

Techniques Used: Isolation, Staining, Standard Deviation

Similar Products

anti her2 erbb2 rabbit polyclonal primary antibody (Cell Signaling Technology Inc)

Cell Signaling Technology Inc anti her2 erbb2 rabbit polyclonal primary antibody

anti her2 erbb2 rabbit polyclonal primary antibody - by Bioz Stars, 2023-06

96/100 stars

Buy from Supplier

Image Search Results

Journal: Advanced Science

Article Title: An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

doi: 10.1002/advs.202102414

Figure Lengend Snippet: HER2 expression and cell cycle distribution in JIMT‐1 and N87 cells. a) HER2 expression in JIMT‐1 and N87 cells stained via ICC (red, Alexa 594‐stained HER2; blue, Hoechst‐stained nuclei, scale bar, 10 µm). Cell cycle distribution in b) JIMT‐1 and c) N87 cells treated with T‐DM1, LCB‐ADC1, or LCB‐ADC2 at 0.25 µg mL −1 for 72 h. Cells stained with propidium iodide (PI) were analyzed by flow cytometry.

Article Snippet: After thorough washing with PBS, the cells were incubated with anti‐HER2/ErbB2 rabbit polyclonal primary antibody (#2242S; Cell Signaling, Danvers, MA), anti‐ α ‐tubulin rabbit monoclonal primary antibody (#2125S; Cell Signaling), and Alexa 594 or 488 antirabbit IgG (Jackson Immuno Research, West Grove, PA).

Techniques: Expressing, Staining, Flow Cytometry

Journal: Advanced Science

Article Title: An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

doi: 10.1002/advs.202102414

Figure Lengend Snippet: Therapeutic efficacy of LCB‐ADCs in HER2‐positive CDX models and microtubule interruption and mitotic arrest in CDX tumor tissue. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in JIMT‐1 cells. Drugs were i.v. injected at 2 mg kg −1 once (↑), n = 5. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC1 or 2). b) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in N87 cells. Drugs were i.v. injected at 2 mg kg −1 once (↑), n = 5. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC 2). HER2 expression in tumor tissue was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c) In vivo microtubule interruption and mitotic arrest by LCB‐ADC1. Mice bearing N87 tumors were i.v. administered with T‐DM1, LCB‐ADC1 at 5 mg kg −1 once. After 10 d, the tumors were isolated, fixed, and stained with anti‐ α ‐tubulin (upper, blue, Hoechst‐stained nuclei; red, Alexa 594‐stained α ‐tubulin, scale bar; 10 µm) or antiphosphohistone H3 (PHH3) (lower, blue, hematoxylin‐stained nuclei; brown, 3,3′‐diaminobenzidine (DAB)‐stained PHH3, scale bar, 100 µm). d) Effect of LCB‐ADC1 in N87 cells. Drugs were i.v. injected at 0.2, 1 or 5 mg kg −1 , once a week for 4 weeks (↑), n = 8. Data values are the mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC1).

Techniques: Injection, Standard Deviation, Expressing, Staining, In Vivo, Isolation

Journal: Advanced Science

Article Title: An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

doi: 10.1002/advs.202102414

Figure Lengend Snippet: Therapeutic efficacy of LCB‐ADCs in HER2‐positive GC PDX models. a) Effect of LCB‐ADC1, LCB‐ADC2, T‐DM1 in an HER2 +++ GC PDX model. The drugs were i.v. injected at 5 mg kg −1 once (↑), n = 5. b) Effect of LCB‐ADC1, LCB‐ADC3, T‐DM1 in an HER2 ++ GC PDX model. Drugs were i.v. injected at 5 mg kg −1 twice (↑), n = 5. Data values are a mean ± standard deviation. ** p < 0.01 (T‐DM1 vs LCB‐ADC3, single or repeated treatment). HER2 expression in tumor tissues was detected by IHC (brown, DAB‐stained HER2; blue, hematoxylin‐stained nuclei, scale bar, 10 µm). c,d) Mice bearing HER2 ++ GC patient‐derived tumors were i.v. administered with LCB‐ADC1, LCB‐ADC3, or T‐DM1 at 5 mg kg −1 , every other week for 4 weeks, n = 5. At the end of the experiment, c) tumors were isolated, photographed (scale bar, 1 cm) and d) weighed. Data values are mean ± standard deviation. * p < 0.05 (T‐DM1 vs LCB‐ADC1), ** p < 0.01 (T‐DM1 vs LCB‐ADC3).

Techniques: Injection, Standard Deviation, Expressing, Staining, Derivative Assay, Isolation

Journal: Advanced Science

Article Title: An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

doi: 10.1002/advs.202102414

Figure Lengend Snippet: In vivo efficacy of LCB‐ADC3 at a low dose in an HER2 ++ GC PDX model. a) Tumor growth delay curves and b) survival rate when the tumor volume reached 1500 mm 3 . Mice bearing patient‐derived tumors were i.v. administered LCB‐ADC3 (0.5 or 1 mg kg −1 ) or T‐DM1 (4 mg kg −1 ), weekly for 4 weeks (↑), n = 5. Data values are the mean ± standard deviation. ** p < 0.01 (T‐DM1 vs LCB‐ADC3, 0.05 mg kg −1 ), *** p < 0.001 (T‐DM1 vs LCB‐ADC3, 1 mg kg −1 ).

Techniques: In Vivo, Derivative Assay, Standard Deviation

Journal: Advanced Science

Article Title: An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2‐Antibody‐Drug Conjugate against Refractory HER2‐Positive Cancers

doi: 10.1002/advs.202102414

Figure Lengend Snippet: Mitotic arrest of HER2‐positive GC PDX tumor tissue. a,b) Mice bearing HER2‐positive PDX tumors were i.v. administered with a) LCB‐ADC2, b) LCB‐ADC3 or T‐DM1 at 5 mg kg −1 once, n = 5. After 1, 4, and 7 d, the tumors were isolated, fixed, and stained with antiphosphohistone H3 (PHH3) (blue, hematoxylin‐stained nuclei; brown, DAB‐stained PHH3, scale bar, 100 µm). Data values are a mean ± standard deviation. *** p < 0.001 (T‐DM1 vs LCB‐ADC2 or 3).

Techniques: Isolation, Staining, Standard Deviation